Panitumumab-IRDye800 Glowing Dye to Help Spot Brain Tumors During Surgery
Tests panitumumab-IRDye800 as a surgical imaging dye in adults having brain lesions removed.
Plain-language title generated from the registry record
Registry title: Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Key facts
- Where
- Nashville, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eben Rosenthal
- Trial code
- NCT07493447
- Record updated
- 16 October 2026
- Original description
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.Read full original descriptionShow less
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
Inclusion: Subjects with intracranial lesions undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are deemed to be candidates for resection; Subject age ≥ 18 years; Adequate hematologic and end-organ function appropriate for surgery and panitumumab infusion as determined by routine preoperative evaluation or designee prior to infusion. If liver function, renal function, and hematologic laboratory test results are acceptable for elective surgery and panitumumab infusion, the patient is considered eligible for the study. Laboratory results will need to be obtained within 30 days prior to initiation of study treatment include:; Chemistry Panel - Potassium, BUN (or urea), and Creatinine; CBC with differential - WBC, including ANC, hemoglobin, hematocrit, and platelet count; Magnesium and Phosphorus; Women of childbearing potential must have a negative pregnancy test within 7 days of study drug administration; Ability to understand and willingness to sign a written informed document or written informed consent via a surrogate consent rider from the patients' healthcare decision maker.
Exclusion: Had a myocardial infarction, cerebrovascular accident, or uncontrolled chronic heart failure within 6 months prior to enrollment; Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents; History of infusion reactions to any monoclonal antibody therapies; Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis; Patients with severe renal disease or anuria; Magnesium or phosphorus lower than normal institutional values, and subject is symptomatic; Women who are currently pregnant or breastfeeding; Participants presenting with a baseline QTcF interval > than 480 milliseconds.